ABOVE: © ISTOCK.COM, STEVEN_MOLINA
Update (December 16): The National Institutes of Health in updated COVID-19 treatment guidelines today states that “There is insufficient evidence for the [panel] to recommend either for or against the use of fluvoxamine for the treatment of COVID-19.” The agency lists a number of difficulties in interpreting the TOGETHER trial data, including differences in adherence between the treatment and placebo groups, a risk of bias associated with the per-protocol analysis, and an endpoint with unclear clinical relevance. Meanwhile, the STOP COVID 2 trial has “been stopped for futility by a data safety monitoring board after lower than expected case rates and treatment effect were observed,” according to the update.
A highly publicized new study of the antidepressant fluvoxamine as a potential COVID-19 treatment suggests that the drug could reduce hospitalizations among people with the disease, but has prompted calls for caution in interpreting the findings.
A ...
